Mevacor, Other Statins To Be Considered By California Carcinogen Committee
Executive Summary
California's Carcinogen Identification Committee will evaluate during its Dec. 17 meeting whether all statins should be designated as carcinogens under Proposition 65, rather than Merck's Mevacor (lovastatin) alone